| INTRODUCTION
Atrial fibrillation (AF) is the most common pathological arrhythmia in horses. The arrhythmia may lead to decreased performance and cause safety issues for the rider or driver. 1 Atrial fibrillation leads to electrical, contractile, and structural remodeling of the atria, making successful cardioversion more difficult to achieve with increased AF duration. 2 It is therefore important to know the duration of AF when choosing a treatment strategy for the horse. 3 Cardioversion of AF can be performed pharmacologically with quinidine, which has an efficacy of about 85% in horses with no underlying cardiac disease. 3 However, this treatment frequently results in adverse cardiac or noncardiac reactions, and treatment may need to be terminated before
Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; bpm, beats per minute; BW, body weight; HR, heart rate; HR rest , resting heart rate; JTc, corrected JT interval; QTc, corrected QT interval cardioversion. The search for alternative solutions is therefore ongoing, and antiarrhythmic drugs tested in horses include flecainide, [4] [5] [6] amiodarone, 7, 8 propafenone, 9 sotalol, 10 NS8593, 11 dofetilide, and ranolazine. 12 Some of these drugs have only been tested in an experimental setting, 11, 12 whereas others also have shown some effect in naturally occurring AF. 7, 8 Flecainide is a class Ic antiarrhythmic drug that blocks sodium currents and thereby slows intramyocardial conduction. Electrophysiological studies in horses have shown an increase in the AF cycle length preceding cardioversion, but no effect on the atrial effective refractory period. 4, 6 Studies on flecainide for cardioversion of AF have provided conflicting results. High efficacy was seen in horses with experimentally induced AF, 4, 5 but flecainide was only effective in 1 of 10 horses with naturally occurring AF and in 41% of horses with recent-onset AF. 6, 13 Reported adverse effects include agitation, restlessness, neck sweating, decreased borborygmi 5, 14 and several cases of ventricular proarrhythmia and sudden death. 6, [15] [16] [17] Flecainide resulted in widening of the QRS complex 4, 6, 15 and 1 study also reported prolongation of the QT interval. 4 Flecainide is widely used for cardioversion and the maintenance of sinus rhythm in humans suffering from AF. Guidelines for selecting treatments in human AF patients indicate that flecainide can be used for those with recentonset AF and no other major cardiac abnormalities such as hypertension, ischemia, or impaired left ventricular function. 18, 19 We hypothesized that the antiarrhythmic effects of flecainide in horses are dependent on the duration of AF. Information on the maximum duration of AF allowing for cardioversion with flecainide would help to guide clinicians considering flecainide as a treatment option.
Therefore, the aim of our study was to test flecainide treatment in horses with induced AF at selected time points and different AF durations.
| MATERIALS AND METHODS

| Horses
Nine Standardbred mares were studied; 6 in an AF group (horses 1-6) and 3 in a group of sham-operated time-matched controls (horses 7-9). The AF group had a mean age of 10 AE 3 years (range, 20 with a portable ultrasound unit with a phased array transducer (Vivid I and 3S Phased Array transducer, GE Healthcare, Horten, Norway). The present study was part of a larger study on chronic AF development in horses, and the same horses were therefore included in other studies.
The study was approved by the local ethical committee at the 43 In brief, the horses were restrained in a stock, The animals were tied to prohibit lying down or rolling for 1 week after the procedure, and the experiments began after a recovery period of 3 weeks.
| Study protocol
An overview of the study protocol is presented in Figure 1 
| AF induction
A pacemaker was used to induce AF by burst-pacing (20 seconds, 10 Hz, pulse amplitude 7.5 mV, pulse width 1.5 ms) in the right atrium.
Burst-pacing was limited to strains of 20 seconds by the pacemaker.
These strains were delivered on a daily basis (1-8 hours per horse)
until AF was self-sustained. In between burst-pacing sessions, the pacemaker was set to stimulate in an inhibitory mode with an atrial rate of 170 per minute (pulse amplitude 2.5 mV, pulse width 0.4 ms) from each lead, leaving the horse with an atrial paced rhythm of 340 per minute. This practice ensured that the atria were not left in sinus rhythm but constantly were subjected to a fast rate throughout the study. Self-sustained AF was defined as AF of >10 minutes duration without stimulation from the pacemaker. When self-sustained AF had reached a duration of more than 24 hours, the pacemaker was switched off. The horses were subsequently auscultated daily to confirm AF.
| ECG recordings
Electrocardiograms were recorded throughout each procedure day with a Holter unit with 2 separate channels and bipolar leads as previously described. 4 Additionally ECGs were recorded between procedure days to assess heart rhythm if auscultation was not feasible. During AF induction, ECG was continuously recorded. If a horse was in self-sustained AF after a burst-pacing session, the Holter unit remained on to assess if and when cardioversion occurred, but if AF was not self-sustained and the horse was left with an atrial paced rhythm over night, the Holter unit was removed until burst-pacing was initiated again. The cumulative duration of AF (including all periods of self-sustained AF) for each horse was assessed by analyzing the ECG recordings and documented auscultations. Burst-pacing, pacemaker activity, and time periods of unknown activity in the atria were not included.
Heart rate at rest (HR rest ) was measured for all horses before day 0 on surface ECGs obtained between 8 PM and 6 AM, because the horses were undisturbed in their stables during this period. Three time-points at which the heart rate (HR) was low and stable were chosen from the heart rate view (Televet) and HR was measured as an average of 10 beats for each time point. The HR rest was calculated again in the AF group once AF was self-sustained, and on day 27 or 55 of the study (minimum, 11 hours after flecainide infusion) for the control group. The mean HR before flecainide infusion was calculated for all horses by averaging all RR intervals for 30 minutes before the start of infusion.
The QRS durations and QT intervals were manually analyzed in lead II at 4 different time points: before, 1 minute after, 30 minutes after, and 60 minutes after the end of flecainide infusion. Five repeated measurements were performed at each time point. The QT measurements were corrected according to HR with a piecewise linear regression model, 21 and JTc intervals were calculated as QTc minus QRS. To identify abnormal QRS complexes, ECGs were manually analyzed 30 minutes before, during and 30 minutes after the end 
| Statistical analysis
Data are presented as mean AE SD when normally distributed and without SD when the distribution was not normal. The cumulative duration of AF for responders (cardioversion to sinus rhythm after flecainide infusion) and nonresponders (no cardioversion) was compared using an unpaired t test. The time (min) to cardioversion was log transformed before performing linear regression of the time to cardioversion as a function of the cumulative AF duration (in days). We compared the mean HR rest before and after the start of the study in both the AF group and the controls by paired t tests (GraphPad Prism 5 software, GraphPad Software, San Diego, CA). A linear mixed model including heart rhythm (AF or sinus rhythm) and study day was used to test the correlation between number of abnormal QRS complexes after flecainide infusion and mean HR before infusion. Analyses of QRS duration, JTc and QTc also were performed by a linear mixed model (R 3.3.1 software, The R Foundation for Statistical Computing, Vienna, Austria). The QRS duration and QTc after flecainide infusion were compared for the AF group and the controls by an unpaired t test. P ≤ .05 was considered to be significant.
| RESULTS
On day 3, only 1 horse had self-sustained AF and this horse cardio- Examples of both single abnormal QRS complexes and an episode of consecutive abnormal QRS complexes after infusion of flecainide are shown in Figure 6 . Detomidine (5 mg) was administered to 2 of the horses with consecutive abnormal QRS complexes (Table 1) 
| DISCUSSION
Ours is the first systematic study to investigate the time-dependent ability of flecainide to terminate AF in horses. The results indicate that flecainide could be considered for the cardioversion of short-duration AF, but also that great caution should be used because the potential adverse effects include sudden death. The HR rest during AF was markedly increased for some horses. A correlation was found between HR and the number of abnormal QRS complexes in the ventricles after flecainide infusion. Furthermore, the horses experiencing episodes of consecutive abnormal QRS complexes were those with the highest HR rest . Abnormal QRS complexes were observed in the AF group before flecainide infusion, and to a greater extent after flecainide infusion, confirming the ventricular proarrhythmicity of flecainide. FIGURE 4 Mean heart rate at rest. Mean heart rate at rest (HR rest ) for the individual horses measured on surface baseline ECG "start" and after pacing "end" in control and AF groups. The line and error bars reflect the mean AE SD. *** = P < 0.001
Ventricular effects of flecainide administration. QRS duration (A) and corrected QT intervals (QTc) (B) before and after flecainide treatment in all horses (n = 9) presented in box plots with whiskers from minimum to maximum values. # Represents the significance level of the comparison between the time points after flecainide infusion and the baseline ( ### = P < 0.001). * = P < 0.05, *** = P < 0.001
With flecainide use, all horses in AF cardioverted on days 3 and 9, and 5 of 6 horses cardioverted on day 27, whereas only 2 of 6 horses cardioverted on day 55 after the start of AF induction. These results correlate with those of previous studies, which found flecainide to be effective in induced AF of very short duration (15 minutes), 4, 5 but not in naturally occurring chronic AF. 6, 14 In 1 study, naturally occurring AF with a duration of 12 days could be terminated by flecainide infusion, 6 and in another study, flecainide was effective in 2 cases of naturally occurring AF. 5 Furthermore, flecainide was reported to cardiovert 12 of 29 horses with recent-onset AF. 13 These findings suggest that the effects seen with flecainide are not restricted to experimentally induced AF. Because the horses in our study did not develop AF naturally, they may lack some of the cardiovascular factors leading to AF. A certain degree of remodeling is necessary for AF to be self-sustained, creating the substrate for the maintenance of AF. 22 The cumulative duration of AF in this protocol referred only to self-sustained AF, implying that remodeling must have been present, mimicking naturally occurring AF. The remodeling we Number of horses experiencing single or coupled abnormal QRS complexes and number of horses experiencing episodes of consecutive abnormal QRS complexes in separate columns. The number of abnormal complexes and episodes of consecutive abnormal complexes are specified in brackets with the number for each horse separated by "/". * indicates that some of the abnormal QRS complexes are coupled. # indicates that detomidine was administered. AF = atrial fibrillation; Before = 30 min before flecainide infusion; Flecainide = during and 30 min after flecainide infusion.
FIGURE 6
Abnormal ECG findings after flecainide infusion. Single abnormal QRS complexes (A) and an episode of consecutive abnormal QRS complexes (B). The QRS complexes were classified as abnormal because they display the R-on-T phenomenon. All ECG examples are lead II. * indicates abnormal complexes expect to be present is electrical and contractile remodeling which was seen in horses after 4 and 12 hours of induced AF, respectively. 15 Furthermore, structural remodeling has been found in goats after 1 week of pacing-induced AF, which likely also occurred in these horses. 23 The time from the start of flecainide infusion to cardioversion was correlated with the cumulative duration of AF. This finding demonstrates the process of remodeling and the importance of knowing AF duration when selecting a therapeutic regimen.
Comparing cardioversion and the cumulative duration of selfsustained AF, flecainide appears to be a plausible treatment option in AF with a duration <2 weeks, provided great caution is taken because the drug may cause severe adverse effects, including sudden death.
The horse that did not cardiovert on day 27 also had the longest duration of self-sustained AF (18.3 days). In human medicine, flecainide primarily is used for acute onset AF (<48 hours), and its reported efficacy is between 52 and 95%. 24 A consensus statement indicated that in horses with AF, cardioversion should not be attempted before 24-48 hours of documented AF because of the chance of spontaneous cardioversion. 1 In humans, lack of early intervention may, however, cause recurrence of AF in the long term, and early cardioversion may lower the risk of relapse. 25 This can be explained by the electrophysiological remodeling that occurs within a few hours of AF, which facilitates persistence of the arrhythmia. 15, 22 Both horses that responded to flecainide on day 55 showed a change from fine to coarse AF before cardioversion to sinus rhythm.
The coarse AF likely represents an increase in the atrial fibrillation cycle length as seen previously after flecainide infusion in horses. 4, 26 In humans, conversion from AF to atrial flutter (AFL) with class Ic antiarrhythmic compounds is a known complication. By slowing down conduction velocity, flecainide can transform the unorganized multiple microreentry circuits in the atria during AF into a single organized macroreentry circuit that is seen as AFL on the ECG. 27 Because class
Ic antiarrhythmic drugs do not slow atrioventricular conduction, a risk of 1:1 atrioventricular conduction with wide QRS tachycardia exists. 28, 29 In these horses, the coarse AF terminated without further treatment and no 1:1 conduction through the atrioventricular node was observed. Pharmacological cardioversion of AFL tends to be difficult 30, 31 and AFL is not well-characterized in horses. These considerations led us to avoid defining coarse AF as AFL.
Whether abnormal QRS complexes such as those encountered in our study are caused by re-entry phenomena in the ventricle or rapid atrioventricular conduction must be elucidated further. In humans, ventricular tachycardia often is caused by re-entry involving some degree of damage in the cardiac tissue, or triggered activity after delayed repolarization. 32 Because both single and consecutive abnormal QRS complexes occurred in the AF group without the influence of flecainide and ventricular damage because of AF seems improbable, aberrant conduction appears to be the most likely cause. However, because we were unable to determine the origin of the abnormal complexes, no classification was made. Fast atrial rhythm (eg, AF with a slow cycle length or AFL) in combination with an atrioventricular node capable of conducting these high rates into the ventricles poses a risk for severe, life-threatening arrhythmias. 33 The incidence consequently is increased by the presence of adrenergic stimulation, 34 and the general advice is to administer atrioventricular nodal blocking drugs such as β-blockers or nondihydropyridine calcium channel antagonists along with class Ic antiarrhythmic drugs in humans. 19 Flecainide has a high affinity for sodium channels in the open state and the effect is therefore strongly use dependent. 35 Flecainide also has some blocking effects on potassium channels, but this effect is decreased at higher HRs (reverse use dependency). 36 Consequently, increased HR will result in a greater decrease in ventricular conduction velocity by flecainide and could lead to increased risk of re-entry arrhythmias. 37 This substantiates the recommendation of concurrent rate control during flecainide treatment.
A wide QRS tachycardia after flecainide administration previously has been reported in horses, and a slowing of the ventricular rate with the alpha 2-adrenoreceptor agonist detomidine was able to terminate the dysrhythmia. 6 Detomidine administration causes bradycardia by inhibiting the sympathetic nervous system and increasing vagal tone as a response from the baroreceptors to hypertension induced by initial alpha-2β adrenoreceptor stimulation. 38, 39 In accordance with this effect, no further abnormal QRS complexes were seen in the 2 horses in which detomidine was infused in our study. No rate-controlling drugs were administered with flecainide to the horse that received the double dose and we therefore do not know whether slowing the atrioventricular conduction would have abrogated the occurrence of ventricular fibrillation. Flecainide also can cause monomorphic ventricular tachycardia in humans and it may be challenging to distinguish between this rhythm and 1:1 conduction of AFL. 33 However, based on the successful use of detomidine in preventing further consecutive abnormal QRS complexes in these horses, it seems likely that what we observed was 1:1 conduction of the supraventricular tachycardia.
These findings strongly indicate that flecainide should be used in conjunction with a rate-controlling drug in horses, but additional investigations are warranted.
Flecainide infusion prolonged the QRS duration and QTc interval. The QRS duration reflects ventricular conduction velocity, and prolongation was expected and corresponded with the findings from previous studies. [4] [5] [6] After flecainide infusion, the QRS duration was longer in the AF horses compared to the controls and one could speculate that this could have contributed to the occurrence of abnormal QRS complexes. As seen in Table 1 , these primarily occurred when the horses were in AF. Prolongation of the QTc interval is not consistently reported in horses. One study found a prolongation only at higher doses of flecainide, 5 whereas a second study found prolongations similar to what we observed. 4 We could show that the ventricular repolarization was prolonged independently from QRS prolongation by calculating the JTc interval. This prolongation is linked to the risk of torsades de pointes ventricular tachycardia in humans. 40 However, flecainide does not induce JTc prolongation in humans, and flecainide-induced torsades de pointes ventricular tachycardia is rare. 41, 42 A JTc prolongation after flecainide infusion also was found in another study, 4 but the association between this prolongation and torsades de pointes ventricular tachycardia in horses remains to be proven.
Spontaneous cardioversion rates after experimentally induced AF of hours or days in duration is difficult to predict because limited information is available in the literature. One study found that 4/6 horses subjected to pacing-induced AF of 7 day's duration cardioverted spontaneously within 3 days of no pacing. 15 Our study did not include any control horses receiving saline, which would have allowed us to study spontaneous cardioversion. This design feature is a limitation of this study as we are unable to tell whether spontaneous cardioversion may have occurred on the specified procedure days. However, the fact that most AF episodes were self-sustained for hours to weeks before treatment, and cardioversion was 
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